McKesson (NYSE:MCK) EVP Francisco Fraga Sells 600 Shares of Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 600 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $1,050.00, for a total value of $630,000.00. Following the transaction, the executive vice president owned 5,064 shares in the company, valued at approximately $5,317,200. This trade represents a 10.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Francisco Fraga also recently made the following trade(s):

• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The shares were sold at an average price of $995.80, for a total value of $796,640.00.

McKesson Price Performance

NYSE MCK traded up $10.56 on Thursday, reaching $1,080.00. The stock had a trading volume of 839,263 shares, compared to its average volume of 917,913. The firm has a fifty day moving average of $931.17 and a two-hundred day moving average of $865.74. McKesson Corporation has a 1-year low of $723.68 and a 1-year high of $1,121.50. The company has a market cap of $125.92 billion, a P/E ratio of 28.98, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The firm had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter last year, the business earned $9.86 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Research analysts predict that McKesson Corporation will post 44.71 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 1st. McKesson’s dividend payout ratio (DPR) is currently 10.06%.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, ahead of analysts’ roughly $10.70–$10.72 estimates, while revenue of $110.96 billion topped expectations of $109.9 billion and grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: The company raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty distribution, higher prescription volumes and GLP-1 momentum as growth drivers. McKesson Corp (MCK) Q2 2027 Earnings Call Highlights
• Positive Sentiment: TD Cowen and Evercore ISI each raised their price target to $1,200, from $1,006 and $1,000, respectively—signaling improved analyst expectations after the results. TD Cowen Adjusts Price Target Evercore ISI Adjusts Price Target
• Neutral Sentiment: McKesson closed its $2.25 billion Precision Medicine Group acquisition, expanding its position in precision medicine. The deal offers growth potential, with execution and integration still to come. McKesson Outlook and Precision Medicine Deal
• Negative Sentiment: Some investors appeared cautious despite the earnings beat, with reports describing an after-hours stock dip. Earlier coverage also flagged branded-drug pricing pressure as a potential headwind. Q2 Earnings and Outlook

Institutional Trading of McKesson

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Secure Asset Management LLC boosted its holdings in shares of McKesson by 484.8% in the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock valued at $1,604,000 after purchasing an additional 1,760 shares in the last quarter. Royal London Asset Management Ltd. increased its stake in shares of McKesson by 1.1% in the 2nd quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock valued at $84,809,000 after purchasing an additional 1,216 shares during the last quarter. BayBridge Capital Group LLC raised its holdings in shares of McKesson by 268.0% during the 2nd quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock worth $1,468,000 after buying an additional 1,415 shares in the last quarter. Benchmark Investment Advisors LLC acquired a new position in shares of McKesson during the 2nd quarter worth $441,000. Finally, Summit Global Investments bought a new stake in shares of McKesson during the 2nd quarter worth $1,159,000. Institutional investors own 85.07% of the company’s stock.

Analysts Set New Price Targets

MCK has been the subject of several analyst reports. Bank of America lifted their price objective on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. Mizuho raised their target price on shares of McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Barclays lifted their price target on shares of McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Wednesday, August 19th. Finally, Royal Bank Of Canada boosted their price target on McKesson from $845.00 to $965.00 and gave the company a “sector perform” rating in a research note on Thursday. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,011.82.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.